This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Companies Competing to Gain Lead in Ovarian Cancer Market
by Zacks Equity Research
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Stock Market News For Nov 22, 2017
by Zacks Equity Research
Benchmarks finished in the green on Tuesday following gains in the technology and healthcare sectors
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Amgen (AMGN) Unveils Auto Injector Device for Enbrel in US
by Zacks Equity Research
Amgen launched its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.
Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion
by Zacks Equity Research
Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.
Cancer Space Update: Label Expansion for Three Major Drugs
by Zacks Equity Research
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
by Zacks Equity Research
AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day
by Arpita Dutt
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis
by Zacks Equity Research
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study
by Zacks Equity Research
Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat
by Zacks Equity Research
Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.
Pharma ETFs Down Post Q3 Earnings
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs as they saw rough trading over the past one month.
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Increased operating expenses mar Aerie's (AERI) Q3 performance.
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah
by Arpita Dutt
It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.
Dow 30 Stock Roundup: Chevron, Exxon, Apple Earnings Impress
by Swarup Gupta
The Dow continued to notch up gains during a week marked by key legislative developments.
Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.
Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows
by Zacks Equity Research
Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.
AmerisourceBergen (ABC) Beats Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Solid growth in the Pharmaceutical Distribution Services segment drove AmerisourceBergen's (ABC) top line in the fourth quarter.
Company News For Nov 1, 2017
by Zacks Equity Research
Companies in the news are: PFE, UA,AET, ACOR
Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.
Stocks To Watch Out For This Halloween
by Zacks Equity Research
Stocks To Watch Out For This Halloween
Will Markets Stay Spooked This Halloween?
by Mark Vickery
While econ data looks favorable, ahead of the opening bell we also see plenty of strength in Q3 performance.